Skip to content
KAMURAROOTED IN WELLNESS
Growth hormone axis / VISUAL FIELD GUIDE

IGF-LR3

IGF-LR3 is a modified IGF-1 analogue used in experimental research. It is distinct from licensed IGF-1 medicines.

Explore in the human body ↗
01 / FOLLOW THE BIOLOGY

From signal to response.

Hormone axisSIGNAL → GLAND → TISSUESchematic explanation · not a measured treatment response
STEP 1 OF 3

Modified growth factor

The analogue changes IGF-1 interactions.

Pathway sources: [1] [2]

02 / SYMPTOMS & STUDIED USES

What are you trying to understand?

Choose a concern to see the research context. A symptom is a starting point for assessment, not a treatment selection.

Clinical evidence gap

Muscle gain / recovery

Experimental growth signalling is not evidence of safe or effective physique enhancement.

Examine the supporting research ↓
03 / KEEP THE CONTEXT

The details that change the interpretation.

Formulation & route

Do not substitute evidence for mecasermin or native IGF-1 for LR3.

Bring to the discussion

Does the study concern this exact IGF analogue?

04 / SOURCE TRAIL

Go beyond the summary.

01

Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.

pubmed.ncbi.nlm.nih.gov · Open source ↗
02

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

pubmed.ncbi.nlm.nih.gov · Open source ↗
More research already linked in Kamura (2)

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. · 2026

Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. · 2025

My Stack

0 treatments

🧪

Your stack is empty. Browse treatments and click + to build your protocol.